Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Gurski L, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):874-901. doi: 10.6004/jnccn.2018.0061.

PMID:
30006429
2.

Anal Carcinoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Benson AB 3rd, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Jul;16(7):852-871. doi: 10.6004/jnccn.2018.0060.

PMID:
30006428
3.

Promising New Agents for Colorectal Cancer.

Das S, Ciombor KK, Haraldsdottir S, Goldberg RM.

Curr Treat Options Oncol. 2018 May 11;19(6):29. doi: 10.1007/s11864-018-0543-z. Review.

PMID:
29752549
4.

NCCN Guidelines Insights: Colon Cancer, Version 2.2018.

Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA.

J Natl Compr Canc Netw. 2018 Apr;16(4):359-369. doi: 10.6004/jnccn.2018.0021.

PMID:
29632055
5.

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.

El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF.

Cancer Chemother Pharmacol. 2018 Apr;81(4):659-670. doi: 10.1007/s00280-018-3517-8. Epub 2018 Feb 21.

PMID:
29468455
6.

Hypermutated Tumors and Immune Checkpoint Inhibition.

Ciombor KK, Goldberg RM.

Drugs. 2018 Feb;78(2):155-162. doi: 10.1007/s40265-018-0863-0.

PMID:
29350327
7.

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer.

Ciombor KK, Bekaii-Saab T.

Oncologist. 2018 Jan;23(1):25-34. doi: 10.1634/theoncologist.2017-0203. Epub 2017 Oct 11. Review.

8.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

9.

A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis.

Ahn DH, Krishna K, Blazer M, Reardon J, Wei L, Wu C, Ciombor KK, Noonan AM, Mikhail S, Bekaii-Saab T.

Ther Adv Med Oncol. 2017 Feb;9(2):75-82. doi: 10.1177/1758834016676011. Epub 2016 Nov 2.

10.

Diagnosis and Diagnostic Imaging of Anal Canal Cancer.

Ciombor KK, Ernst RD, Brown G.

Surg Oncol Clin N Am. 2017 Jan;26(1):45-55. doi: 10.1016/j.soc.2016.07.002. Review.

PMID:
27889036
11.

A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.

Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J.

Invest New Drugs. 2017 Feb;35(1):95-104. doi: 10.1007/s10637-016-0406-z. Epub 2016 Nov 16.

12.

Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable.

Ciombor KK, Goldberg RM.

JAMA Oncol. 2016 Oct 10. doi: 10.1001/jamaoncol.2016.3777. [Epub ahead of print] No abstract available.

PMID:
27722749
13.

Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy.

Ciombor KK, Goldberg RM.

JAMA Oncol. 2016 Dec 1;2(12):1537-1538. doi: 10.1001/jamaoncol.2016.3642. No abstract available.

PMID:
27684887
14.

Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.

Zhu J, Deane NG, Lewis KB, Padmanabhan C, Washington MK, Ciombor KK, Timmers C, Goldberg RM, Beauchamp RD, Chen X.

Sci Rep. 2016 Sep 14;6:33273. doi: 10.1038/srep33273.

15.

Update on Anti-Angiogenesis Therapy in Colorectal Cancer.

Ciombor KK, Goldberg RM.

Curr Colorectal Cancer Rep. 2015 Dec;11(6):378-387.

16.

Genomic diversity of colorectal cancer: Changing landscape and emerging targets.

Ahn DH, Ciombor KK, Mikhail S, Bekaii-Saab T.

World J Gastroenterol. 2016 Jul 7;22(25):5668-77. doi: 10.3748/wjg.v22.i25.5668. Review.

17.

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.

Noonan AM, Farren MR, Geyer SM, Huang Y, Tahiri S, Ahn D, Mikhail S, Ciombor KK, Pant S, Aparo S, Sexton J, Marshall JL, Mace TA, Wu CS, El-Rayes B, Timmers CD, Zwiebel J, Lesinski GB, Villalona-Calero MA, Bekaii-Saab TS.

Mol Ther. 2016 Jun;24(6):1150-1158. doi: 10.1038/mt.2016.66. Epub 2016 Apr 4.

18.

How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?

Ciombor KK, Haraldsdottir S, Goldberg RM.

Curr Colorectal Cancer Rep. 2014 Dec 1;10(4):372-379.

19.

Recent therapeutic advances in the treatment of colorectal cancer.

Ciombor KK, Wu C, Goldberg RM.

Annu Rev Med. 2015;66:83-95. doi: 10.1146/annurev-med-051513-102539. Epub 2014 Oct 9. Review.

PMID:
25341011
20.

Nuclear factor of activated T-cell activity is associated with metastatic capacity in colon cancer.

Tripathi MK, Deane NG, Zhu J, An H, Mima S, Wang X, Padmanabhan S, Shi Z, Prodduturi N, Ciombor KK, Chen X, Washington MK, Zhang B, Beauchamp RD.

Cancer Res. 2014 Dec 1;74(23):6947-57. doi: 10.1158/0008-5472.CAN-14-1592. Epub 2014 Oct 15.

21.

Targeting metastatic colorectal cancer - present and emerging treatment options.

Ciombor KK, Berlin J.

Pharmgenomics Pers Med. 2014 Jul 8;7:137-44. doi: 10.2147/PGPM.S47582. eCollection 2014. Review.

22.

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.

Ciombor KK, Feng Y, Benson AB 3rd, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J.

Invest New Drugs. 2014 Oct;32(5):1017-27. doi: 10.1007/s10637-014-0111-8. Epub 2014 Jun 4.

23.

Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer.

Ciombor KK, Goldberg RM.

Hepat Oncol. 2014 Jun;1(3):331-345. doi: 10.2217/hep.14.13. Epub 2014 Sep 9. Review.

24.

Aflibercept--a decoy VEGF receptor.

Ciombor KK, Berlin J.

Curr Oncol Rep. 2014 Feb;16(2):368. doi: 10.1007/s11912-013-0368-7. Review.

25.

Current therapy and future directions in biliary tract malignancies.

Ciombor KK, Goff LW.

Curr Treat Options Oncol. 2013 Sep;14(3):337-49. doi: 10.1007/s11864-013-0237-5.

26.

Aflibercept.

Ciombor KK, Berlin J, Chan E.

Clin Cancer Res. 2013 Apr 15;19(8):1920-5. doi: 10.1158/1078-0432.CCR-12-2911. Epub 2013 Feb 26.

27.

Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis.

Gehrie E, Neff AT, Ciombor KK, Harris N, Seegmiller AC, Young PP.

Transfusion. 2012 Jan;52(1):4-5. doi: 10.1111/j.1537-2995.2011.03407.x. Epub 2011 Oct 27. No abstract available.

PMID:
22032241
28.

Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.

Merchan JR, Ferrell A, Macintyre J, Ciombor KK, Levi J, Ribeiro A, Sleeman D, Flores A, Lopes G, Rocha-Lima CM.

Am J Clin Oncol. 2012 Oct;35(5):446-50.

PMID:
21552097

Supplemental Content

Loading ...
Support Center